Quality Inspector

Nemera launches bi-dose nasal spray solution. 3 September 2026 Drug delivery device company Nemera has announced its DuoSpray bi-dose nasal spray platform, a 'non-invasive, needle free' administration alternative for systemic nasal therapies. The company adds that the platform is designed to offer 'rapid onset of action' and enable patients to self-administer without intervention from healthcare professionals. DuoSpray delivers two metered doses within a single device for acute therapies. The new solution compliments the company's commercially available UniSpray platform, which is most suitable for lifesaving and crisis applications. When combined, Nemera says the two solutions provide a platform for systemic intramucosal nasal administration, with various formats depending on the intended use, drug posology and product-specific development strategy. According to Nemera, DuoSpray's robust design makes it compatible with industry-standard primary containers and conventional filling lines, seeking to de-risk industrialization and help accelerate development timelines. The solution can deliver 200 μL of liquid formulation through two metered doses of 100μL with an integrated visual dose indicator. It also features a broad labelling surface and can be customized depending on product-specific needs. In related news, earlier this year Lindal Group introduced its Snap, Luna and Matteo actuator solutions designed to expand its portfolio across healthcare, personal care and homecare applications, including nasal formulations and aluminium spray cans. Snap is a spray head actuator specifically designed for nasal applications within the healthcare market, available in adult and child versions and featuring a mechanical break-up spray system to ensure 'controlled and effective' delivery. The following month saw Aptar Closures reveal its new range of inverted lidless dispensing closures for the beauty and personal care markets. The line's Cleo and Airy closures aim to help eliminate the need for separate lids and provide a ready-to-dispense packaging format that reduces unwanted product waste.

Nemera and SCHOTT Pharma deliver verified pen injector platform with sterile cartridge system. * Nemera's pen injector platform verified with SCHOTT Pharma's cartriQ(R) 3 mL ready-to-use glass cartridge system * Compatibility testing confirms seamless and reliable integration of delivery device and primary packaging, ensuring optimal device performance and patient safety * Partnership supports growing demand for patient-centric injectable therapies in homecare settings Lyon, France, July 2026 - To support the industry shift from hospital to homecare and a more convenient drug administration for patients, Nemera, a world-leading provider of drug delivery device solutions and combination product services, and SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, have strengthened their partnership to provide pharmaceutical companies with a reliable, fully verified platform for injectable therapies. "As healthcare increasingly moves closer to patients, pharmaceutical companies need to combine drug containment and delivery from the outset," says Christian Mias, CEO of SCHOTT Pharma. "Together with Nemera, we are helping them address this growing demand through a proven and compatible platform solution." "Our collaboration with SCHOTT Pharma reflects our commitment to providing integrated drug delivery solutions that help simplify development and accelerate time to market", says Marc Hämel, CEO of Nemera. "At Nemera, we believe that strong partnerships are essential to helping pharmaceutical companies bring combination products to patients more efficiently." Strategic partnership to address evolving patient needs. As therapeutic combination products require seamless integration between the delivery device and the pharmaceutical primary packaging system, Nemera's and SCHOTT Pharma's partnership supports optimal product performance as well as patient safety and comfort. With more than two decades of experience in high-volume manufacturing of pen injectors and autoinjectors, Nemera offers a comprehensive portfolio of proprietary pen injector platforms developed with full intellectual property ownership. These platforms are designed to accommodate a broad range of prescription therapies, address diverse patient needs, and are manufactured in Nemera's state-of-the-art facilities using advanced automation technologies. At the same time, SCHOTT Pharma's cartriQ(R) ready-to-use (RTU) glass cartridge system, manufactured from FIOLAX(R) Type I borosilicate glass with controlled hydrolytic resistance, is specifically designed to meet the demanding requirements of pen injectors, autoinjectors, and pump systems. Its robust mechanical resistance, excellent cosmetic quality, and tight dimensional tolerances support precise processing and reliable device functionality. Quality is ensured through 100% camera-controlled inspection, while geometric tolerances exceed ISO 13926-1 standards and can be further tightened for highly demanding applications. Precisely controlled inner and outer diameters of the cartridge contribute to improved manufacturing robustness, enhanced visual inspection performance, and greater dose accuracy. In particular, tightly controlled inner diameters help minimize overfill losses in multidose applications, while advanced defect detection capabilities support cartridge integrity, sterility, and overall product quality. Verified compatibility reduces risk and accelerates development. A comprehensive study was conducted by Nemera's laboratory in Poland on the mechanical and chemical performance of 3 mL cartriQ(R) RTU cartridges. The evaluation focused on critical performance parameters, including break-loose and gliding forces (BLGF), as well as inorganic and organic leachable profiles, following accelerated aging conditions. Testing was performed in accordance with recognized industry standards, including ISO 21881 and ICH Q3D guidelines. To further assess compatibility, additional assessments covered dimensional accuracy, filling volume performance, air-bubble evaluation, and density measurements. SCHOTT Pharma's glass cartridge system met all predefined acceptance criteria, demonstrating excellent compatibility with Nemera's pen injector platforms and providing high confidence in the combined solution. The successful completion of these evaluations confirms the full technical compatibility between the respective products from Nemera and SCHOTT Pharma. Pharmaceutical companies can therefore benefit from a commercially available, verified integrated solution that accelerates development timelines while mitigating technical risks associated with combination products. Together, Nemera and SCHOTT Pharma are committed to supporting pharmaceutical partners with high-quality, reliable solutions for injectable drug delivery - ultimately helping patients access treatments that are safe, effective, and easy to use. About Nemera. Nemera is a world-leading provider of drug delivery device solutions and combination product services. Its mission of putting patients first drives Packaging Connections Pvt Ltd. to design and manufacture devices that maximize treatment efficacy. From early device strategy to state-of-the-art manufacturing, Packaging Connections Pvt Ltd. is committed to delivering the highest quality standards to its customers. For more information, visit: www.nemera.net About SCHOTT Pharma. Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. Further information at www.schott-pharma.com [email protected] Contact Person Coraline Cortot

Nemera announces the construction of a new 5,000 sqm production hall at its La Verpillière site. Published: 14/04/2026 Nemera, a global leader in drug delivery devices, announces the groundbreaking ceremony for a new production hall at its La Verpillière site (Isère, France). This major 5,000 sqm extension, 4,500 sqm of which will be dedicated to manufacturing, marks an important milestone in the Group's growth ambitions. Expanding capacity to support Nemera's growth Construction work will take place throughout 2026, with production scheduled to start in the second half of 2027. This project is fully aligned with Nemera's industrial roadmap, which aims to double the size of the La Verpillière site by 2030, confirming its strategic role in the Group's global development. The expansion responds to rapidly growing global demand, in particular for injection pens used in the treatment of diabetes and obesity, two major public health challenges. It will sustainably increase production capacity to better support customers and meet patients' needs. A project serving the local community At full capacity by 2028, the new production hall will create 150 additional jobs, strengthening a workforce that already exceeds 600 employees at La Verpillière. This recruitment momentum illustrates the Group's commitment to local economic development and to enhancing the attractiveness of the region. Environmentally responsible construction The future production hall has been designed to meet stringent environmental standards. Highly energy-efficient technologies have been selected to control energy consumption and reduce carbon footprint. The building will include 1,500 sqm of photovoltaic panels, and from 2027 its operations will fall within the scope of the ISO 14001 and ISO 50001 certifications already in place at the La Verpillière site. Groundbreaking ceremony The official groundbreaking ceremony took place on April 14, 2026, at the La Verpillière site, in the presence of Nemera representatives, industrial partners and local institutional stakeholders. Julien Marion, Plant Director of Nemera La Verpillière, stated: "We are extremely proud of the devices we develop and manufacture at Nemera La Verpillière, as they help improve the health of millions of patients around the world every day. This new expansion reflects the trust our customers place in us and the quality of our teams' work, whose expertise and rigor are essential to delivering projects of this scale. We are also fortunate to be located at the heart of the CAPI, a dynamic industrial region that actively supports our development. Through this project, we are strengthening our contribution to the local economy as a major employer." About Nemera Nemera is a world-leading provider of drug delivery device solutions. Its mission of putting patients first drives Nemera France SAS to design and manufacture devices that maximize treatment efficacy. From early device strategy to state-of-the-art manufacturing, Nemera France SAS is committed to delivering the highest quality standards to its customers.